Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (22)
Keisuke Miwa, Eiji Oki, Yasunori Emi, Hiroshi Saeki, Tetsuya Kusumoto, Yoshito Akagi, Yutaka Ogata, Hironori Samura, Shoji Tokunaga, Hiroshi Ishikawa, Takaho Tanaka, Susumu Sueyoshi, Hidefumi Higashi, Hiroyuki Matsuda, Tetsuo Touyama & Yoshihiko Maehara. (2015) Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). International Journal of Clinical Oncology 21:1, pages 110-117.
Crossref
Crossref
Veli Berk, Kemal Deniz, Oktay Bozkurt, Ersin Ozaslan, Halit Karaca, Mevlude Inanc, Ayse Ocak Duran & Metin Ozkan. (2015) Predictive Significance of VEGF and HIF-1? Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab. Asian Pacific Journal of Cancer Prevention 16:14, pages 6149-6154.
Crossref
Crossref
Jens Sperling, David Brandhorst, Thilo Sch?fer, Christian Ziemann, Anna Benz-Wei?er, Claudia Scheuer, Otto Kollmar, Martin K. Schilling & Michael D. Menger. (2012) Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clinical & Experimental Metastasis 30:4, pages 447-455.
Crossref
Crossref
Jens Sperling, Thilo Sch?fer, Anna Benz-Wei?er, Christian Ziemann, Claudia Scheuer, Otto Kollmar, Martin K. Schilling & Michael D. Menger. (2012) Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases. International Journal of Colorectal Disease 28:4, pages 555-562.
Crossref
Crossref
Keiji Hirata, Hiromitsu Matsuda, Takayuki Toyonaga, Yukio Sonoda, Hidetoshi Kiyonaga, Yohei Tominaga, Ryuichi Mibu, Masashi Miyazaki & Hiroyuki Kobayashi. (2013) Successful Management with Splenectomy for Splenomegaly with Thrombocytopenia and Leukocytopenia Caused by Oxaliplatin-based Chemotherapy for Metastatic Colon Cancer. A Case Report. Nippon Daicho Komonbyo Gakkai Zasshi 66:6, pages 422-427.
Crossref
Crossref
Eiji Oki, Yasunori Emi, Yoshito Akagi, Shoji Tokunaga, Noriaki Sadanaga, Takaho Tanaka, Yutaka Ogata, Hiroshi Saeki, Yoshihiro Kakeji, Hideo Baba, Tadashi Nishimaki, Shoji Natsugoe, Kazuo Shirouzu & Yoshihiko Maehara. (2013) Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701). Oncology 84:4, pages 233-239.
Crossref
Crossref
Robert C. G. MartinIIII, Charles R. Scoggins, Dana Tomalty, Marshall Schreeder, Tiffany Metzger, Clifton Tatum & Vivek Sharma. (2012) Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial. Journal of Gastrointestinal Surgery 16:8, pages 1531-1538.
Crossref
Crossref
Kaiyumars Contractor, Amarnath Challapalli, Giampaolo Tomasi, Lula Rosso, Harpreet Wasan, Justin Stebbing, Laura Kenny, Stephen Mangar, Pippa Riddle, Carlo Palmieri, Adil Al-Nahhas, Rohini Sharma, Federico Turkheimer, R Charles Coombes & Eric Aboagye. (2012)
Imaging of cellular proliferation in liver metastasis by [
18
F]fluorothymidine positron emission tomography: effect of therapy
. Physics in Medicine and Biology 57:11, pages 3419-3433.
Crossref
Crossref
Jaafar Bennouna, Christophe Borg, Jean-Pierre Delord, Faress Husseini, Véronique Trillet-Lenoir, Roger Faroux, Eric François, Marc Ychou, François Goldwasser, Olivier Bouché, Helene Senellart, Sandrine Kraemer & Jean-Yves Douillard. (2012) Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. Clinical Colorectal Cancer 11:1, pages 38-44.
Crossref
Crossref
Jens Sperling, Thilo Schäfer, Christian Ziemann, Anna Benz-Weißer, Otto Kollmar, Martin K. Schilling & Michael D. Menger. (2011) Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clinical & Experimental Metastasis 29:2, pages 91-99.
Crossref
Crossref
Jérome Solassol, Jeanne Ramos, Evelyne Crapez, Majda Saifi, Alain Mangé, Evelyne Vianès, Pierre-Jean Lamy, Valérie Costes & Thierry Maudelonde. (2011) KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues. International Journal of Molecular Sciences 12:5, pages 3191-3204.
Crossref
Crossref
Shweta R. Urva, Victor C. Yang & Joseph P. Balthasar. (2010) Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody. Journal of Pharmaceutical Sciences 99:3, pages 1582-1600.
Crossref
Crossref
Han Hong LeeHoon HurSoo Hong KimAe Ryung ParkWook KimHae Myung Jeon. (2010) Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis. Cancer Research and Treatment 42:1, pages 18.
Crossref
Crossref
M. Keese, V. Yagublu, K. Schwenke, S. Post & P. Bastiaens. (2009) Fluorescence lifetime imaging microscopy of chemotherapy‐induced apoptosis resistance in a syngenic mouse tumor model. International Journal of Cancer 126:1, pages 104-113.
Crossref
Crossref
Mohamed Hebbar, François-René Pruvot, Olivier Romano, Jean-Pierre Triboulet & Aimery de Gramont. (2009) Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer. Cancer Treatment Reviews 35:8, pages 668-675.
Crossref
Crossref
Kenji Kobayashi, Mariko Abe, Nobuhisha Ueda, Tomohisa Sato, Masaaki Azuma, Fumika Hanatate, Yukio Shimizu, Yoko Ikeda, Toshiki Matubara & Hidetoshi Matsunami. (2009) A Case of Poorly Differentiated Rectal Adenocarcinoma Causing Disseminated Intravascular Coagulation Syndrome Due to Carcinomatosis of Bone Marrow after a Modified FOLFIRI-induced Pathological CR. Nippon Daicho Komonbyo Gakkai Zasshi 62:1, pages 65-71.
Crossref
Crossref
Mitsukuni Suenaga, Nobuyuki Mizunuma, Daigo Shouji, Eiji Shinozaki, Satoshi Matsusaka, Keisho Chin, Masatoshi Oya, Toshiharu Yamaguchi, Tetsuichiro Muto & Kiyohiko Hatake. (2008) Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. Journal of Gastroenterology 43:11, pages 842-848.
Crossref
Crossref
Francesco Recchia, Giampiero Candeloro, Stefano Necozione, Massimo Bratta, Roberta Bisegna & Silvio Rea. (2008) Alternating XELFOX and XELFIRI in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology 31:4, pages 323-328.
Crossref
Crossref
H Y Sheikh, J W Valle, T Waddell, K Palmer, G Wilson, A Sjursen, O Craven, R Swindell & M P Saunders. (2008) Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. British Journal of Cancer 99:4, pages 577-583.
Crossref
Crossref
Seth Politano, Michael Overman, Priyanka Pathak, Romil Chadha, Katrina Glover, David Z. Chang, Robert A. Wolff, Paulo M. Hoff, James Abbruzzese, Cathy Eng & Scott Kopetz. (2008) Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clinical Colorectal Cancer 7:1, pages 55-59.
Crossref
Crossref
David J. Gallagher & Nancy Kemeny. (2008) Second-Line Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer 7:1, pages 25-32.
Crossref
Crossref
Lawrence Leichman. (2007) The Role of Chemotherapy in the Curative Treatment of Patients with Liver Metastases from Colorectal Cancer. Surgical Oncology Clinics of North America 16:3, pages 537-556.
Crossref
Crossref